Bleeding time and thromboembolism in ERα, ERβ, or ERα AF-1⁰ hematopoietic chimeric mice. (A) Tail-bleeding times of control mice (WT) engrafted with normal bone marrow (ERα^+/+ and ERβ^+/+) and treated or not with E2. (B) Tail-bleeding times of ERα^−/− and ERβ^−/− bone marrow chimeras treated or not with E2. (C) Mice engrafted with normal bone marrow or (D) with bone marrow from ERα^−/− or ERβ^−/− mice were treated or not with E2 and thromboembolism assays were performed as in Figure 5. Fourteen of 15 mice engrafted with ERα^−/− bone marrow died whereas all (7 of 7) mice engrafted with ERβ^−/− survived. (E) Thromboembolism assays were performed in mice engrafted with ERα AF-1⁰ bone marrow and treated or not with E2. All non-E2–treated mice (8 of 8) died, whereas all E2-treated mice (9 of 9) survived.